Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-275291 in HIV-Related Kaposi's Sarcoma
NCT00024024Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2001
- Primary completion
- Aug 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rebimastat in Kaposi sarcoma (KS), sponsored by National Cancer Institute. Primary endpoint: Change in percent of apoptotic cells on tumor biopsies. Started Aug 2001; status: completed.
02
Drugs
rebimastat
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT00024024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024024.